Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects

Isamu Okamoto, Kazuhiko Nakagawa

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The identification of oncogenic genomic alterations is expected to facilitate the development of new molecularly targeted therapies for cancer. EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer (NSCLC). A small-molecule tyrosine kinase inhibitor of ALK, crizotinib, shows pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK, and it has rapidly entered into daily clinical practice. This review focuses on the biology and clinical features of, as well as diagnostic testing for, EML4-ALK-positive NSCLC. Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed.

Original languageEnglish
Pages (from-to)1391-1396
Number of pages6
JournalCancer Science
Volume103
Issue number8
DOIs
Publication statusPublished - Aug 1 2012
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Oncogenes
Protein-Tyrosine Kinases
MAP4
anaplastic lymphoma kinase
Neoplasms
crizotinib

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer : Molecular and clinical aspects. / Okamoto, Isamu; Nakagawa, Kazuhiko.

In: Cancer Science, Vol. 103, No. 8, 01.08.2012, p. 1391-1396.

Research output: Contribution to journalReview article

@article{93528e6c072c4860bc4fbd26172a2d43,
title = "Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects",
abstract = "The identification of oncogenic genomic alterations is expected to facilitate the development of new molecularly targeted therapies for cancer. EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer (NSCLC). A small-molecule tyrosine kinase inhibitor of ALK, crizotinib, shows pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK, and it has rapidly entered into daily clinical practice. This review focuses on the biology and clinical features of, as well as diagnostic testing for, EML4-ALK-positive NSCLC. Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed.",
author = "Isamu Okamoto and Kazuhiko Nakagawa",
year = "2012",
month = "8",
day = "1",
doi = "10.1111/j.1349-7006.2012.02327.x",
language = "English",
volume = "103",
pages = "1391--1396",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer

T2 - Molecular and clinical aspects

AU - Okamoto, Isamu

AU - Nakagawa, Kazuhiko

PY - 2012/8/1

Y1 - 2012/8/1

N2 - The identification of oncogenic genomic alterations is expected to facilitate the development of new molecularly targeted therapies for cancer. EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer (NSCLC). A small-molecule tyrosine kinase inhibitor of ALK, crizotinib, shows pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK, and it has rapidly entered into daily clinical practice. This review focuses on the biology and clinical features of, as well as diagnostic testing for, EML4-ALK-positive NSCLC. Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed.

AB - The identification of oncogenic genomic alterations is expected to facilitate the development of new molecularly targeted therapies for cancer. EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer (NSCLC). A small-molecule tyrosine kinase inhibitor of ALK, crizotinib, shows pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-ALK, and it has rapidly entered into daily clinical practice. This review focuses on the biology and clinical features of, as well as diagnostic testing for, EML4-ALK-positive NSCLC. Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed.

UR - http://www.scopus.com/inward/record.url?scp=84864301306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864301306&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02327.x

DO - 10.1111/j.1349-7006.2012.02327.x

M3 - Review article

C2 - 22568572

AN - SCOPUS:84864301306

VL - 103

SP - 1391

EP - 1396

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -